SecBot SecBot
PRESS-RELEASE ·Filed Aug 6, 2026

LXRX

Lexicon Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock will trade on pipeline catalysts rather than current financials. Monitor SONATA-HCM topline data in Q1 2027 and ZYNQUISTA NDA resubmission in Q4 2026 as the primary value drivers. The $190.6M cash position provides runway through these events, reducing near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

LXRX drug pipeline →

ZYNQUISTA

◆ Mixed Named in this press release
Impact
Phase
Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
Time to market
Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
Next catalyst
None dated

What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.36
T+0 close · Aug 6, 2026 · via day close
Latest settled
−39.83%
T+60 · $1.42
Vs SPY
−38.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $2.36entry
  2. T+1 · 3mo ago +4.66%α +4.05% · $2.47
  3. T+5 · 3mo ago −0.85%α −2.06% · $2.34
  4. T+20 · 3mo ago −4.24%α −4.84% · $2.26
  5. T+60 · 18d ago −39.83%α −38.16% · $1.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27.6M Novo Nordisk licensing milestone, and a net loss of $31.8M ($0.07/share) vs net income of $3.3M a year ago. The key catalysts are the completion of SONATA-HCM enrollment (topline Q1 2027) and ZYNQUISTA NDA resubmission expected Q4 2026, with $190.6M cash providing runway through these events.

Key Financial Metrics

EPS
$0.00
est −$0.05 · +100.0%
Revenue
$692.0K
est $4.0M · -82.7% · -97.6% YoY
Rating
in line

Key Facts

  • Q2 2026 total revenue $0.7M vs $28.9M in Q2 2025 (included $27.6M licensing milestone from Novo Nordisk)
  • Net loss $31.8M ($0.07/share) vs net income $3.3M ($0.01/share) in Q2 2025
  • SONATA-HCM Phase 3 enrollment completed on time, substantially exceeding 500-patient target; topline results expected Q1 2027
  • ZYNQUISTA NDA resubmission for type 1 diabetes anticipated Q4 2026
  • Cash and investments $190.6M as of June 30, 2026, up from $125.2M at year-end 2025
  • Entered $100M loan facility with Hercules Capital in May 2026; initial $55M tranche funded

Financial Impact

Revenue decline of $28.2M YoY driven by absence of one-time licensing milestone; net loss widened by $35.0M YoY

revenuenet incomecash

Risk Factors

  • SONATA-HCM Phase 3 failure or mixed results would be a major setback
  • ZYNQUISTA NDA resubmission could face delays or additional FDA requirements
  • Cash burn rate of ~$16M/quarter may require additional financing before catalysts mature
  • INPEFA commercial revenue remains minimal ($0.7M/quarter) with unclear path to profitability

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3340161

Track record

16 reports on LXRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Viewing Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026